公开(公告)号：US20210323947A1

公开(公告)日：2021-10-21

申请号：US17235120

申请日：2021-04-20

Applicant: Novartis AG ,  Katholieke Universiteit Leuven ,  Korea Research Institute of Chemical Technology

Inventor： Johan NEYTS ,  Daniel POON ,  Keith Bruce PFISTER

IPC: C07D405/12 ,  C07D405/14 ,  C07D307/93 ,  A61K45/06 ,  A61P31/14

Abstract: The invention provides compounds of Formula (I): as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections.

公开(公告)号：US20250092036A1

公开(公告)日：2025-03-20

申请号：US18800559

申请日：2024-08-12

Applicant: Novartis AG

Inventor： Erich W. BAUM ,  Thomas A. DINEEN, JR. ,  Jonathan Edward HEMPEL ,  Matthew James HESSE ,  Robert KOENIG ,  Matthew James LAMARCHE ,  Jay Francis LARROW ,  Ruowei MO ,  Henrik MOEBITZ ,  Rukundo NTAGANDA ,  Keith Bruce PFISTER ,  Martin SENDZIK ,  Colin Keith SKEPPER ,  Joseph WZOREK, JR. ,  Frédéric ZECRI

IPC: C07D471/04 ,  A61K31/454 ,  A61K31/4545 ,  A61P35/00 ,  C07D401/06 ,  C07D405/14 ,  C07D491/052

Abstract: The invention relates to compounds which modulate the activity of ERK. The present invention also relates to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, and use of said compounds in the treatment of conditions, diseases and disorders mediated by ERK.

公开(公告)号：US20250090491A1

公开(公告)日：2025-03-20

申请号：US18797480

申请日：2024-08-07

Applicant: Novartis AG ,  Katholieke Universiteit Leuven ,  Korea Research Institute of Chemical Technology

Inventor： Johan NEYTS ,  Daniel POON ,  Keith Bruce PFISTER ,  Young-Sik JUNG ,  Soo Bong HAN ,  Yashwardhan R. MALPANI ,  Prashant CHAKRASALI ,  Sang-Ho LEE ,  Chong-Kyo LEE ,  Chonsaeng KIM ,  Jin Soo SHIN ,  Hae Soo KIM

IPC: A61K31/343 ,  A61P31/14 ,  C07D307/93

Abstract: This disclosure provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections.

公开(公告)号：US20200270252A1

公开(公告)日：2020-08-27

申请号：US16808985

申请日：2020-03-04

Applicant: Novartis AG

Inventor： Jiping FU ,  Wooseok HAN ,  Subramanian KARUR ,  Peichao LU ,  Keith Bruce PFISTER ,  Joseph Michael YOUNG

IPC: C07D471/14 ,  C07D405/12 ,  A61P31/12 ,  C07D491/16 ,  C07D401/12 ,  A61K45/06 ,  A61K31/4985 ,  C07D471/22

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20210322362A1

公开(公告)日：2021-10-21

申请号：US17235140

申请日：2021-04-20

Applicant: Novartis AG ,  Katholieke Universiteit Leuven ,  Korea Research Institute of Chemical Technology

Inventor： Johan NEYTS ,  Daniel POON ,  Keith Bruce PFISTER

IPC: A61K31/343 ,  C07D307/93 ,  A61P31/14

Abstract: This disclosure provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections.

公开(公告)号：US20190300530A1

公开(公告)日：2019-10-03

申请号：US16383382

申请日：2019-04-12

Applicant: Novartis AG

Inventor： Jiping FU ,  Wooseok HAN ,  Subramanian KARUR ,  Peichao LU ,  Keith Bruce PFISTER ,  Joseph Michael YOUNG

IPC: C07D471/14 ,  C07D401/12 ,  C07D491/16 ,  A61P31/12 ,  A61K45/06 ,  C07D471/22 ,  A61K31/4985 ,  C07D405/12

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20210346377A1

公开(公告)日：2021-11-11

申请号：US16956527

申请日：2018-12-19

Applicant: Novartis AG

Inventor： Jiping FU ,  Wooseok HAN ,  Xianming JIN ,  Keith Bruce PFISTER ,  Joseph Michael YOUNG

IPC: A61K31/4985 ,  C07D471/14 ,  A01N43/90 ,  A61K45/06 ,  A61K47/60 ,  A61K38/21 ,  A61P31/20

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions and pharmaceutical combinations containing such compounds, as well as methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus (HBV), and for reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20190247392A1

公开(公告)日：2019-08-15

申请号：US16210968

申请日：2018-12-05

Applicant: Novartis AG

Inventor： Jeffrey T. BAGDANOFF ,  Yu DING ,  Wooseok HAN ,  Zilin HUANG ,  Qun JIANG ,  Xianming JIN ,  Xiang KOU ,  Patrick LEE ,  Mika LINDVALL ,  Zhongcheng MIN ,  Yue PAN ,  Sabina PECCHI ,  Keith Bruce PFISTER ,  Daniel POON ,  Vivek RAUNIYAR ,  Xiaojing Michael WANG ,  Qiong ZHANG ,  Jianguang ZHOU ,  Shejin ZHU

IPC: A61K31/497 ,  A61K31/5355 ,  A61K31/4436 ,  A61K31/4433 ,  A61K31/44 ,  C07D403/06 ,  C07D401/12 ,  C07D401/06 ,  C07D213/73 ,  C07D413/14 ,  C07D241/20 ,  C07D401/04 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D498/04 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/553 ,  A61K45/06

Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

公开(公告)号：US20180312507A1

公开(公告)日：2018-11-01

申请号：US15965172

申请日：2018-04-27

Applicant: Novartis AG

Inventor： Jiping FU ,  Wooseok HAN ,  Subramanian KARUR ,  Peichao LU ,  Keith Bruce PFISTER ,  Joseph Michael YOUNG

IPC: C07D471/14 ,  C07D405/12 ,  C07D401/12 ,  C07D491/16 ,  A61P31/12

CPC classification number: C07D471/14 ,  A61K31/4985 ,  A61K45/06 ,  A61P31/12 ,  C07D401/12 ,  C07D405/12 ,  C07D471/22 ,  C07D491/16

Abstract: The invention provides compounds of Formula (I) as described herein, along with pharmaceutically acceptable salts, pharmaceutical compositions containing such compounds, and methods to use these compounds, salts and compositions for treating viral infections, particularly infections caused by hepatitis B virus, and reducing the occurrence of serious conditions associated with HBV.

公开(公告)号：US20180028532A1

公开(公告)日：2018-02-01

申请号：US15672568

申请日：2017-08-09

Applicant: Novartis AG

Inventor： Jeffrey T. BAGDANOFF ,  Yu DING ,  Wooseok HAN ,  Zilin HUANG ,  Qun JIANG ,  Xianming JIN ,  Xiang KOU ,  Patrick LEE ,  Mika LINDVALL ,  Zhongcheng MIN ,  Yue PAN ,  Sabina PECCHI ,  Keith Bruce PFISTER ,  Daniel POON ,  Vivek RAUNIYAR ,  Xiaojing Michael WANG ,  Qiong ZHANG ,  Jianguang ZHOU ,  Shejin ZHU

IPC: A61K31/497 ,  A61K31/4433 ,  A61K31/5355 ,  A61K31/44 ,  A61K31/4436

CPC classification number: A61K31/497 ,  A61K31/44 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/553 ,  A61K45/06 ,  A61K2121/00 ,  C07D213/73 ,  C07D241/20 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D413/14 ,  C07D498/04

Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.